Lataa...
MicroRNA-218 enhances gastric cancer cell cisplatin sensitivity by targeting survivin
Gastric cancer (GC) is one of the most prevalent types of cancer worldwide. Cisplatin based chemotherapy is the primary strategy implemented for the treatment of G; however, chemoresistance is a major problem. Previous studies have indicated that microRNAs (miRs) are associated with chemoresistance...
Tallennettuna:
| Julkaisussa: | Exp Ther Med |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
D.A. Spandidos
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6257577/ https://ncbi.nlm.nih.gov/pubmed/30542435 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2018.6802 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|